4.1 Article

Identification of 2,4-diamino-6,7-dimethoxyquinoline derivatives as G9a inhibitors

期刊

MEDCHEMCOMM
卷 5, 期 12, 页码 1821-1828

出版社

ROYAL SOC CHEMISTRY
DOI: 10.1039/c4md00274a

关键词

-

资金

  1. Royal Thai Government Scholarship
  2. EPSRC-funded Institute of Chemical Biology Doctoral Training Centre
  3. European Commission [299857]
  4. AbbVie
  5. Boehringer Ingelheim
  6. Canada Foundation for Innovation
  7. Canadian Institutes for Health Research
  8. Genome Canada through the Ontario Genomics Institute [OGI-055]
  9. GlaxoSmithKline
  10. Janssen
  11. Lilly Canada
  12. Novartis Research Foundation
  13. Ontario Ministry of Economic Development and Innovation
  14. Pfizer
  15. Takeda
  16. Wellcome Trust [092809/Z/10/Z]

向作者/读者索取更多资源

G9a is a histone lysine methyltransferase (HKMT) involved in epigenetic regulation via the installation of histone methylation marks. 6,7-Dimethoxyquinazoline analogues, such as BIX-01294, are established as potent, substrate competitive inhibitors of G9a. With an objective to identify novel chemotypes for substrate competitive inhibitors of G9a, we have designed and synthesised a range of heterocyclic scaffolds, and investigated their ability to inhibit G9a. These studies have led to improved understanding of the key pharmacophoric features of BIX-01294 and the identification of a new core quinoline inhibitory scaffold, which retains excellent potency and high selectivity. Molecular docking was carried out to explain the observed in vitro data.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.1
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据